The Ministry of Health and Welfare's National Health Insurance Administration recently announced that next-generation sequencing (NGS) testing will be included in health insurance coverage starting May 1st, with a total reimbursement of approximately 300 million NT dollars in the first year. The administration stated that for solid tumors, a total of 9 major cancer types can benefit from NGS to assist in selecting appropriate targeted drugs, while for hematologic malignancies, there are 3 cancer types eligible for NGS, with reimbursement being provided through a combination of fixed health insurance payments and out-of-pocket payments by individuals. Solid tumors covered by NGS include non-small cell lung cancer, triple-negative breast cancer, ovarian cancer/fallopian tube cancer/primary peritoneal cancer, prostate cancer, pancreatic cancer, NTRK gene fusion solid tumors, intrahepatic cholangiocarcinoma, thyroid cancer, and medullary thyroid carcinoma; hematologic malignancies include acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), acute lymphoblastic leukemia (B-ALL and T-ALL).
Read more
